Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a pilot phase I study to evaluate the safety and efficacy on elemene injectable
emulsion in treating patients with glioblastoma. Elemene, isolated from the Chinese medicinal
herb Curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor
cells in vitro and in vivo.Elemene injectable emulsion against malignant tumors was low.
Therefore, the effect of Elemene injectable emulsion being used in clinical settings needs to
be confirmed by further RCTs.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University